Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors

References

• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:1079–81
   PubMed Web of Science ®Google Scholar
• Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52:S397–428
   PubMed Web of Science ®Google Scholar
• Klevens RM, Edwards JR, Richards Jr CL, et al. Estimating health care-associated infections and deaths in US hospitals, 2002. Public Health Rep 2007;122:160–6
   PubMed Web of Science ®Google Scholar
• Eber MR, Laxminarayan R, Perencevich EN, Malani A. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 2010;170:347–53
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29–40
   PubMed Web of Science ®Google Scholar
• Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24:71–109
   PubMed Web of Science ®Google Scholar
• East SP, Silver LL. Multitarget ligands in antibacterial research: progress and opportunities. Exp Opin Drug Discov 2013;8:143–56
   PubMed Web of Science ®Google Scholar
• Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J Antibiot 2011;64:413–25
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Benjamin Jr DK, et al. 10 × ’20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013;56:1685–94
   PubMed Web of Science ®Google Scholar
• Maxwell A. DNA gyrase as a drug target. Trends Microbiol 1997;5:102–9
   PubMed Web of Science ®Google Scholar
• Maxwell A, Lawson DM. The ATP binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 2003;3:283–303
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao X. DNA gyrase, topisomerase IV and the 4-quinolones. Microbiol Mol Biol Rev 1997;61:377–92
   PubMed Web of Science ®Google Scholar
• Heisig P. Inhibitors of bacterial topoisomerases: mechanisms of action and resistance and clinical aspects. Planta Med 2001;67:3–12
   PubMed Web of Science ®Google Scholar
• Ferrero L, Cameron B, Manse B, et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 1994;13:641–53
   PubMed Web of Science ®Google Scholar
• Kato J-I, Nishimura Y, Imamura R, et al. New topoisomerases essential for chromosome segregation in E. coli. Cell 1990;63:393–404
   PubMed Web of Science ®Google Scholar
• Deibler RW, Rahmati S, Zechiedrich EL. Topoisomerase IV, alone, unknots DNA in E. coli. Genes Dev 2001;15:748–61
   PubMed Web of Science ®Google Scholar
• Zechiedrich EL, Khodrusky AB, Bachellier S, et al. Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli. J Biol Chem 2000;275:8103–13
   PubMed Web of Science ®Google Scholar
• Fabrega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to quinolones. Microb Biotechnol 2009;2:40–61
   PubMed Web of Science ®Google Scholar
• Bolon MK. The newer fluoroquinolones. Med Clin North Am 2011;95:793–817
   PubMed Web of Science ®Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA, J Am Med Assoc 2003;289:885–8
   PubMed Web of Science ®Google Scholar
• Siwek A, Stączek P, Wujec M, et al. Biological and docking studies of topoisomerase IV inhibition by thiosemicarbazides. J Mol Model 2011;17:2297–303
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disc susceptibility tests; approved standard M2-A9. Wayne (PA): Clinical and Laboratory Standards Institute; 2006
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7. Wayne (PA): Clinical and Laboratory Standards Institute; 2006
   Google Scholar
• Pieczonka AM, Strzelczyk A, Sadowska B, et al. 2013. Synthesis and evaluation of antimicrobial activity of 3-oxido-1H-imidazole-4-carbohydrazides hydrazones. Eur J Med Chem 2013;64:389–95
   Google Scholar
• Zhi Ch, Long Z-y, Manikowski A, et al. Hybrid antibacterials. DNA polymerase–topoisomerase inhibitors. J Med Chem 2006;49:1455–65
   PubMed Web of Science ®Google Scholar
• Wujec M, Kędzierska E, Kuśmierz E, et al. Pharmacological and structure–activity relationship evaluation of 4-aryl-1-diphenylacetyl(thio)semicarbazides. Molecules 2014;19:4745–59
   PubMed Web of Science ®Google Scholar
• Plech T, Wujec M, Siwek A, et al. Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety. Eur J Med Chem 2011;46:241–8
   PubMed Web of Science ®Google Scholar
• Siwek A, Stefańska J, Dzitko K, Ruszczak A. Antifungal effect of 4-arylthiosemicarbazides against Candida species. Search for molecular basis of antifungal activity of thiosemicarbazide derivatives. J Mol Model 2012;18:4159–70
   PubMed Web of Science ®Google Scholar
• Siwek A, Świderek K, Jankowski S. Problems with molecular mechanics implementations on the example of 4-benzoyl-1-(4-methyl-imidazol-5-yl)-carbonylthiosemicarbazide. J Mol Model 2012;18:843–9
   PubMed Web of Science ®Google Scholar
• Siwek A, Stączek P, Kosikowska U, et al. Does dehydrocyclization of 4-benzoylthiosemicarbazides in acetic acid lead to s-triazoles or thiadiazoles? Struct Chem 2012;231:1441–8
   Web of Science ®Google Scholar
• Siwek A, Wujec M, Stefańska J, Paneth P. Antimicrobial properties of 4-aryl-3-(2-methyl-furan-3-yl)-Δ2-1,2,4-triazoline-5-thiones. Phosphorus Sulpur 2009;184:3149–59
   Web of Science ®Google Scholar
• Bax BD, Chan PF, Eggleston DS, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010;466:935–40
   PubMed Web of Science ®Google Scholar
• Eakin AE, Green O, Hales N, et al. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents. Antimicrob Agents Chemother 2012;56:1240–6
   PubMed Web of Science ®Google Scholar
• Siwek A, Stączek P, Stefańska J. Synthesis and structure–activity relationship studies of 4-arylthiosemicarbazides as topoisomerase IV inhibitors with Gram-positive antibacterial activity. Search for molecular basis of antibacterial activity of thiosemicarbazides. Eur J Med Chem 2011;46:5717–26
   PubMed Web of Science ®Google Scholar
• Palace-Berl F, Jorge SD, Pasqualoto KFM, et al. 5-Nitro-2-furfuriliden derivatives as potential anti-trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis. Bioorg Med Chem 2013;21:5395–406
   PubMed Web of Science ®Google Scholar
• Siwek A, Stefańska J, Wawrzycka-Gorczyca I, Wujec M. Synthesis and in vitro antibacterial evaluation of 1-substituted-4-ethoxycarbonylmethylthiosemicarbazides and products of their dehydrocyclization. Heteroatom Chem 2010;21:131–8
   Web of Science ®Google Scholar
• (a) Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12. (b) Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the Medical Community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155–64
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2010
   Google Scholar
• (a) Albanèse J, Léone M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000;44:1356–8. (b) Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865–9. (c) Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281–6
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moellering Jr RC, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006;42:S40–50
   PubMed Web of Science ®Google Scholar